List of Covid-19 Vaccines Approved by WHO: Getting vaccinated could save your life. COVID-19 vaccines provide strong protection against serious illness, hospitalization and death. There is also some evidence that being vaccinated will make it less likely that you will pass the virus on to others, which means your decision to get the vaccine also protects those around you.
Even after getting vaccinated, keep taking precautions to protect yourself, family, friends and anyone else you may come into contact with. COVID-19 vaccines are highly effective, but some people will still get ill from COVID-19 after vaccination. There is also still a chance that you could also pass the virus on to others who are not vaccinated. Stay at least 1 metre away from other people, wear a properly fitted mask over your nose and mouth when you can’t keep this distance, avoid poorly ventilated places and settings, clean your hands frequently, stay home if unwell and get tested, and stay informed about how much virus is circulating in the areas where you travel, live and work
टीका लगवाने से आपकी जान बच सकती है। COVID-19 के टीके गंभीर बीमारी, अस्पताल में भर्ती होने और मृत्यु से मजबूत सुरक्षा प्रदान करते हैं। इस बात के भी कुछ प्रमाण हैं कि टीका लगने से यह संभावना कम हो जाएगी कि आप दूसरों को वायरस देंगे, जिसका अर्थ है कि वैक्सीन प्राप्त करने का आपका निर्णय आपके आस-पास के लोगों की भी रक्षा करता है।
टीका लगवाने के बाद भी, अपनी, परिवार, दोस्तों और किसी अन्य व्यक्ति के संपर्क में आने से बचाने के लिए सावधानी बरतते रहें। COVID-19 के टीके अत्यधिक प्रभावी हैं, लेकिन टीकाकरण के बाद भी कुछ लोग COVID-19 से बीमार होंगे। अभी भी एक मौका है कि आप उन लोगों को भी वायरस पारित कर सकते हैं जिन्हें टीका नहीं लगाया गया है। अन्य लोगों से कम से कम 1 मीटर की दूरी पर रहें, अपनी नाक और मुंह पर ठीक से फिट किया हुआ मास्क पहनें, जब आप यह दूरी नहीं रख सकते हैं, खराब हवादार स्थानों और सेटिंग्स से बचें, अपने हाथों को बार-बार साफ करें, अस्वस्थ होने पर घर पर रहें और जांच करवाएं, और इस बारे में सूचित रहें कि आप जिन क्षेत्रों में यात्रा करते हैं, रहते हैं और काम करते हैं, वहां कितना वायरस फैल रहा है
WHO lists additional COVID-19 vaccines for emergency use and issues interim policy recommendations
- WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG).
- “The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”
- WHO’s Emergency Use Listing (EUL) is a prerequisite for the COVAX Facility vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.
- The EUL assesses the quality, safety and efficacy of COVID-19 vaccines, as well as risk management plans and programmatic suitability, such as cold chain requirements. The assessment is performed by the product evaluation group, composed of regulatory experts from around the world and a Technical Advisory Group (TAG), in charge of performing the risk-benefit assessment for an independent recommendation on whether a vaccine can be listed for emergency use and, if so, under which conditions.
- In the case of the Sinopharm vaccine, the WHO assessment included on-site inspections of the production facility.
- The Sinopharm product is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell). Its easy storage requirements make it highly suitable for low-resource settings. It is the also first vaccine that will carry a vaccine vial monitor, a small sticker on the vaccine vials that change colour as the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.
- WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has also completed its review of the vaccine. On the basis of all available evidence, WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks. Vaccine efficacy for symptomatic and hospitalized diseases was estimated to be 79%, for all age groups combined.
- Few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group. Nevertheless, WHO is not recommending an upper age limit for the vaccine because preliminary data and supportive immunogenicity data suggest the vaccine is likely to have a protective effect in older persons. There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations. WHO therefore recommends that countries using the vaccine in older age groups conduct safety and effectiveness monitoring to make the recommendation more robust.
WHO Emergency Use Listing
- The emergency use listing (EUL) procedure assesses the suitability of novel health products during public health emergencies. The objective is to make medicines, vaccines and diagnostics available as rapidly as possible to address the emergency; while adhering to stringent criteria of safety, efficacy and quality. The assessment weighs the threat posed by the emergency as well as the benefit that would accrue; from the use of the product against any potential risks.
- The EUL pathway involves a rigorous assessment of late phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, quality and a risk management plan. These data are reviewed by independent experts; and WHO teams who consider the current body of evidence on the vaccine under consideration, the plans for monitoring its use; and plans for further studies.
- As part of the EUL process, the company producing the vaccine must commit to continuing to generate data to enable full licensure and WHO prequalification of the vaccine. The WHO prequalification process will assess additional clinical data generated from vaccine trials and deployment on a rolling basis; to ensure the vaccine meets the necessary standards of quality, safety and efficacy for broader availability.
- WHO also listed the Pfizer/BioNTech vaccine for emergency use on 31 December 2020; two AstraZeneca/Oxford COVID-19 vaccines on 15 February 2021, produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India; and COVID-19 vaccine Ad26.COV2.S was developed by Janssen (Johnson & Johnson) on 12 March 2021.
SAGE: List of Covid-19 Vaccines Approved by WHO
- SAGE is the principal advisory group to WHO for vaccines and immunization. It is charged with advising WHO on overall global policies and strategies, ranging from vaccines and technology; research and development, to delivery of immunization and its linkages with other health interventions. SAGE is concerned not just with childhood vaccines and immunization, but all vaccine-preventable diseases.
- So SAGE has issued recommendations on Pfizer (8 January 2021); Moderna (25 January 2021), AstraZeneca (21 April 2021); and Janssen COVID (17 March 2021) vaccines; as well as issued a framework for access and population prioritization roadmap.
- SAGE and EUL are complementary but independent processes. The EUL process is centred on determining if a manufactured product is quality-assured, safe and effective. SAGE is policy-oriented. Policy recommendations for a vaccine are only of value to a vaccination campaign; when the product has been listed or authorized for use. In the context of COVID-19 and due to the pressing need for vaccines, the Secretariat of SAGE; and the EUL team have been working in parallel to allow WHO EUL and policy recommendations; based on the available evidence, to be issued in a synchronized manner.
FAQs on List of Covid-19 Vaccines Approved by WHO
What is the Covax facility for COVID-19 vaccines?
The COVAX Facility is the global pooled procurement mechanism for COVID-19 vaccines; through which COVAX will ensure fair and equitable access to vaccines; for all 190 participating economies, using an allocation framework formulated by the WHO
What are the ingredients in the Covishield vaccine?
The Covishield vaccine includes the following ingredients:
L-Histidine, L-Histidine hydrochloride monohydrate, Magnesium chloride hexahydrate, Polysorbate 80, Ethanol, Sucrose, Sodium chloride, Disodium edetate dihydrate (EDTA), Water for injection.
What is “Long COVID”?
Long COVID is used to describe signs and symptoms that last for; a few weeks or months after having a confirmed or suspected case of COVID-19.
Are there any long-term side effects of the COVID-19 vaccine?
- No long-term side effects of the vaccine are known. Government and healthcare institutions are; monitoring the vaccine administration closely to keep track of any unexpected side effects of the vaccine.
- After the vaccine, your body will require some time (a few weeks) to build immunity against the virus
- टीके के कोई दीर्घकालिक दुष्प्रभाव ज्ञात नहीं हैं। सरकार और स्वास्थ्य संस्थान हैं; वैक्सीन के किसी भी अप्रत्याशित दुष्प्रभाव पर नज़र रखने के लिए वैक्सीन प्रशासन की बारीकी से निगरानी करना।
- टीके के बाद, आपके शरीर को वायरस के खिलाफ प्रतिरक्षा बनाने के लिए कुछ समय (कुछ सप्ताह) की आवश्यकता होगी
Why do some people get fever after taking the COVID-19 vaccine?
This immune response is triggered by an antigen present in the vaccine. The blood flow in the body is increased to increase the circulation of the defensive immune cells in the body. This can lead to an increase in body temperature, which can consequently show up as fever.